Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-07-21
    E.g., 2018-07-21

Articles

51281 items
12:00 AM, Aug 22, 2000  |  BC Extra | Company News

Beckman Coulter and Oncotech to develop cancer diagnostics

The companies will collaborate in the discovery of genetic markers for early stage malignancies in colon, ovarian, breast, prostate and lung cancers. BEC will contribute its automated sample preparation, DNA/RNA hybridization, immunochemistry and flow cytometry...
12:00 AM, Aug 22, 2000  |  BC Extra | Company News

Adherex and BioChem collaboration to develop Exherin

The companies will collaborate to develop Adherex's Exherin compound which targets N-cadherin, the primary adhesive force that tumor blood vessels use to connect to each other. BioChem Pharma (BCHE; TSE:BCH) said the companies will share...
12:00 AM, Aug 22, 2000  |  BC Extra | Top Story

Azulfidine approved for children

Pharmacia (PHA) received FDA approval to market Azulfidine EN-tabs (sulfasalazine) delayed release tablets to treat rheumatoid arthritis (RA) involving five or more diseased joints in children from 6 to 16 who have not responded to...
12:00 AM, Aug 22, 2000  |  BC Extra | Company News

ViroPharma picks CEO

VPHM hired Michel de Rosen as president and CEO. de Rosen joined VPHM's board in May. He is a former chairman and CEO of Rhone-Poulenc Rorer, now part of Aventis (AVE). de Rosen replaces Claude...
12:00 AM, Aug 22, 2000  |  BC Extra | Company News

Amarillo receives Orphan Drug designation

The FDA granted Orphan Drug designation for AMAR's Veldona oral low dose interferon-alpha to treat papillomavirus warts in the oral cavity of HIV positive patients. In February, the FDA granted Orphan Drug designation to Veldona...
12:00 AM, Aug 21, 2000  |  BC Extra | Company News

Packard BioScience to buy array subsidiary

PBSC said that it will acquire GSI Lumonics (GSLI; TSE:LSI) division GSLI Life Sciences for $40 million in cash and $80 million in PBSC stock. The division markets its ScanArray confocal laser scanning detection system...
12:00 AM, Aug 21, 2000  |  BC Extra | Company News

Ilex-Millennium joint venture responds to FDA letter

Millennium & Ilex Partners, a joint venture between ILXO and MLNM, responded to a June complete response letter from the FDA regarding its 1999 BLA for Campath alemtuzumab, a monoclonal antibody to treat advanced B...
12:00 AM, Aug 21, 2000  |  BC Extra | Company News

Aronex NDA amendment accepted

The FDA accepted for review ARNX's NDA amendment for its Atragen tretinoin injectable all-trans retinoic acid to treat patients with acute promyelocytic leukemia (APL) for whom therapy with tretinoin is necessary but for whom intravenous...
12:00 AM, Aug 21, 2000  |  BC Extra | Clinical News

Cel-Sci to begin Phase II trial

CVM said it received approval to begin an additional Phase II dose optimization trial with its Multikine cytokine mixture in the Czech Republic and Poland in 20 patients with previously untreated primary squamous cell carcinoma...
12:00 AM, Aug 21, 2000  |  BC Extra | Clinical News

Inotek identifies PARP as target in hemorrhagic shock

Researchers at Inotek (Beverly, Mass.) and colleagues published in the Proceedings of the National Academy of Sciences that mice lacking Poly(ADP-ribose) polymerase (PARP) were protected from the intestinal permeability and rapid decrease in blood...

Pages